Romain Silhol1, Helen Coupland1, Rebecca F Baggaley1,2, Lori Miller3, Lisa Staadegaard1, Sami L Gottlieb4, James Stannah1,5, Katherine M E Turner6, Peter Vickerman7, Richard Hayes3, Philippe Mayaud3, Katharine J Looker7, Marie-Claude Boily1. 1. MRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, London, United Kingdom. 2. Department of Respiratory Sciences, University of Leicester, Leicester, United Kingdom. 3. London School of Hygiene and Tropical Medicine, London, United Kingdom. 4. Department of Sexual and Reproductive Health and Research, World Health Organization, Geneva, Switzerland. 5. Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montréal, QC, Canada. 6. Bristol Veterinary School, University of Bristol, Bristol, United Kingdom; and. 7. Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom.
Abstract
BACKGROUND: Biological and epidemiological evidence suggest that herpes simplex virus type 2 (HSV-2) elevates HIV acquisition and transmission risks. We improved previous estimates of the contribution of HSV-2 to HIV infections by using a dynamic transmission model. SETTING: World Health Organization regions. METHODS: We developed a mathematical model of HSV-2/HIV transmission among 15- to 49-year-old heterosexual, non-drug-injecting populations, calibrated using region-specific demographic and HSV-2/HIV epidemiological data. We derived global and regional estimates of the contribution of HSV-2 to HIV infection over 10 years [the transmission population-attributable fraction (tPAF)] under 3 additive scenarios, assuming: (1) HSV-2 increases only HIV acquisition risk (conservative); (2) HSV-2 also increases HIV transmission risk (liberal); and (3) HIV or antiretroviral therapy (ART) also modifies HSV-2 transmission risk, and HSV-2 decreases ART effect on HIV transmission risk (fully liberal). RESULTS: Under the conservative scenario, the predicted tPAF was 37.3% (95% uncertainty interval: 33.4%-43.2%), and an estimated 5.6 (4.5-7.0) million incident heterosexual HIV infections were due to HSV-2 globally over 2009-2018. The contribution of HSV-2 to HIV infections was largest for the African region [tPAF = 42.6% (38.0%-51.2%)] and lowest for the European region [tPAF = 11.2% (7.9%-13.8%)]. The tPAF was higher among female sex workers, their clients, and older populations, reflecting their higher HSV-2 prevalence. The tPAF was approximately 50% and 1.3- to 2.4-fold higher for the liberal or fully liberal scenario than the conservative scenario across regions. CONCLUSION: HSV-2 may have contributed to at least 37% of incident HIV infections in the past decade worldwide, and even more in Africa, and may continue to do so despite increased ART access unless future improved HSV-2 control measures, such as vaccines, become available.
BACKGROUND: Biological and epidemiological evidence suggest that herpes simplex virus type 2 (HSV-2) elevates HIV acquisition and transmission risks. We improved previous estimates of the contribution of HSV-2 to HIV infections by using a dynamic transmission model. SETTING: World Health Organization regions. METHODS: We developed a mathematical model of HSV-2/HIV transmission among 15- to 49-year-old heterosexual, non-drug-injecting populations, calibrated using region-specific demographic and HSV-2/HIV epidemiological data. We derived global and regional estimates of the contribution of HSV-2 to HIV infection over 10 years [the transmission population-attributable fraction (tPAF)] under 3 additive scenarios, assuming: (1) HSV-2 increases only HIV acquisition risk (conservative); (2) HSV-2 also increases HIV transmission risk (liberal); and (3) HIV or antiretroviral therapy (ART) also modifies HSV-2 transmission risk, and HSV-2 decreases ART effect on HIV transmission risk (fully liberal). RESULTS: Under the conservative scenario, the predicted tPAF was 37.3% (95% uncertainty interval: 33.4%-43.2%), and an estimated 5.6 (4.5-7.0) million incident heterosexual HIV infections were due to HSV-2 globally over 2009-2018. The contribution of HSV-2 to HIV infections was largest for the African region [tPAF = 42.6% (38.0%-51.2%)] and lowest for the European region [tPAF = 11.2% (7.9%-13.8%)]. The tPAF was higher among female sex workers, their clients, and older populations, reflecting their higher HSV-2 prevalence. The tPAF was approximately 50% and 1.3- to 2.4-fold higher for the liberal or fully liberal scenario than the conservative scenario across regions. CONCLUSION: HSV-2 may have contributed to at least 37% of incident HIV infections in the past decade worldwide, and even more in Africa, and may continue to do so despite increased ART access unless future improved HSV-2 control measures, such as vaccines, become available.
Authors: Emily S Ford; Amalia S Magaret; Cedric W Spak; Stacy Selke; Steve Kuntz; Lawrence Corey; Anna Wald Journal: AIDS Date: 2018-11-13 Impact factor: 4.177
Authors: Georges Reniers; Emma Slaymaker; Jessica Nakiyingi-Miiro; Constance Nyamukapa; Amelia Catharine Crampin; Kobus Herbst; Mark Urassa; Fred Otieno; Simon Gregson; Maquins Sewe; Denna Michael; Tom Lutalo; Victoria Hosegood; Ivan Kasamba; Alison Price; Dorean Nabukalu; Estelle Mclean; Basia Zaba Journal: AIDS Date: 2014-11 Impact factor: 4.177
Authors: Marie-Claude Boily; Rebecca F Baggaley; Lei Wang; Benoit Masse; Richard G White; Richard J Hayes; Michel Alary Journal: Lancet Infect Dis Date: 2009-02 Impact factor: 25.071
Authors: Sharmistha Mishra; Michael Pickles; James F Blanchard; Stephen Moses; Zara Shubber; Marie-Claude Boily Journal: PLoS One Date: 2014-07-09 Impact factor: 3.240
Authors: Katharine J Looker; Nicky J Welton; Keith M Sabin; Shona Dalal; Peter Vickerman; Katherine M E Turner; Marie-Claude Boily; Sami L Gottlieb Journal: Lancet Infect Dis Date: 2019-11-18 Impact factor: 71.421